Bosnalijek buys 19.4% stake in insurer Sarajevo Osiguranje
What's the deal? Bosnian pharmaceutical company Bosnalijek has acquired a 19.4% stake in Sarajevo Osiguranje, a Sarajevo-based insurance firm. The deal marks a cross-sector move by a drugmaker into financial services.
Why now? The acquisition comes as companies in Southeast Europe increasingly diversify their holdings beyond core industries. Bosnalijek, one of Bosnia and Herzegovina's largest pharmaceutical firms, appears to be broadening its investment portfolio.
What could go wrong? Cross-sector acquisitions carry integration and governance risks, particularly when a pharma company steps into insurance — a heavily regulated industry with its own set of complexities. Managing two fundamentally different businesses could stretch management attention and resources.
The signal: The deal reflects a wider pattern of established firms in the Western Balkans using strong balance sheets to snap up stakes in financial services companies. It suggests that corporates in the region see value in diversified holdings, even outside their areas of expertise.
Read more: seenews.com
